CymaBay Therapeutics Inc. (NASDAQ:CBAY) will hold its 2Q20 earnings conference call with the financial community on 10th August 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at www.cymabay.com
Earnings Expectation
CymaBay Therapeutics Inc. is reporting second quarter financial results on Monday 10th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, CBAY is expected to report 2Q20 loss of $ 0.24 per share. For the full year, analysts anticipate loss of $ 0.91 per share bottom line.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease.
